CAS: 1071435-99-8; 1-(2-Methylpyrimidin-5-yl)Ethanamine

相似化合物

2665660-59-1 1071435-92-1 1071435-93-2

上下游产品

CAS号90905-33-2 2-甲基-5-嘧啶甲醛

📜5-(1-Azidoethyl)-2-Methylpyrimidine置于钯 氢气,Silica Gel,甲醇乙酸乙酯,三乙胺体系中,用 乙酸乙酯 用作溶剂,化学反应 16.0H,反应生成1-(2-甲基嘧啶-5-基)乙胺
参考文献:Pyrid-2Yl Fused Heterocyclic Compounds,And Compositions And Uses Thereof
标题:Pyrid-2Yl Fused Heterocyclic Compounds,And Compositions And Uses Thereof
摘要:提供了按照公式1A或1B定义的熔合杂环化合物:其中r1,R2和r3如本文所定义.所提供的化合物及其制剂在哺乳动物中包括人类的预防和治疗各种病症,包括但不限于疼痛,炎症,认知障碍,焦虑,抑郁等.

专利信息

专利号:US-9428490-B2
优先权日:2011-07-29
标 题 :Nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD
权利人:SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD; KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.